Prosigna - Synlab


Breast Cancer Recurrence Risk

Why undergoing this examination?

In recent years, the understanding of breast cancer has evolved significantly, now considered a complex and heterogeneous pathology. Therefore, distinct factors must be considered to determine the patient’s prognosis. Women with early-stage breast cancer expressing estrogen receptors usually have a good prognosis. However, in this population, about 50% of recurrences occur after five years of diagnosis. An imminent need in the management of estrogen receptor-positive breast cancer is to identify women at increased risk for late recurrence. 

What is this exam?

Prosigna (PAM50) was developed based on a PAM50 genetic signature that provides the patient’s risk of recurrence information (ROR – Risk Of Recurrence) based on three factors: tumor size, intrinsic molecular subtype, and tumor proliferation status. 

For whom is it indicated?

Postmenopausal women who have undergone mastectomy due to breast cancer and have the following characteristics: 

  • Hormone receptor-positive, node-negative, stage I and II breast cancer; 
  • Hormone receptor-positive, node-positive (1-3, 4 or more positive nodes), stage II or IIIA breast cancer. 


nCounter Dx Analysis System 


Breast Cancer Recurrence Risk




Guaranteed by the experience of the absolute European leader in laboratory diagnostics. 


  • Validated in two clinical studies that evaluated more than 2,400 postmenopausal women with early-stage breast cancer. 
  • Approved by the regulatory agencies of the United States (FDA) and Europe (EMA) as a prognostic tool in early breast cancer; 
  • Provides the assessment of recurrence risk over up to 10 years and the intrinsic subtype. 


Extra Information 


DOCUMENTATION – Available on the SYNLAB Direct for clients 
  • Informed Consent; 
  • Clinical Questionnaire; 
  • Medical Request. 


  • Fasting is not necessary for the exam. 


Additional Information 

The report includes different parameters: 

  • Lymph node involvement and Intrinsic subtype – risk classification and information for therapeutic guidelines. 
  • ROR– numerical value from 0 to 100 related to the 10-year recurrence risk; 
  • Risk classification: Establishes the risk of recurrence in 10 years, classifying into three possible groups: Low risk, intermediate risk, and high risk. 

Delivery Time 

9 business days 

Sample Type 

Fragment of tumor tissue in a paraffin block (consult material preparation instructions). 

Other exams oncology:

We want to share our news with you!

Stay informed by subscribing to our Newsletter and receive exclusive updates on cutting-edge diagnostic medicine worldwide.

Thank you for signing up to our Newsletter!

This email is already registered!

An error occurred, please try later!

Contact us